57 articles
A Circulation review from Harvard proposes the 'target trial framework' to improve how observational data is used to assess cardiovascular device safety and effectiveness.
Age-related shifts in intestinal T cell populations may silently erode gut barrier function, accelerating the chronic inflammation that drives aging diseases.
Expert reviews compare NMN and NR head-to-head. NMN edges out for muscle and sleep benefits; NR leads for neuroprotection.
A Cochrane review of 37 RCTs finds obesity drugs modestly reduce weight in adolescents, but evidence quality is low and long-term data are absent.
A new review reframes how myeloid cells fuel or fight tumors, pointing to plasticity — not just cell diversity — as the core therapeutic target.
The American Heart Association's 2026 update outlines evidence-based strategies to slow disease progression and protect grafts after CABG.
A head-to-head review of 10 CGM devices for healthy adults, weighing real-world accuracy data against limited longevity evidence.
A landmark 48-RCT Cochrane review finds high-certainty evidence that convalescent plasma does not reduce death in moderate-to-severe COVID-19.
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
Expert reviews of top CGM platforms reveal genuine metabolic insights — but no proof they extend lifespan in healthy adults.
A Dana-Farber review maps the path for personalized cancer vaccines — pinpointing which tumors, timing, and combination strategies will matter most.
Expert reviews compare NMN and NR on human trial data, bioavailability, and top-ranked brands for 2026.
